Tissue Repair Ltd (ASX:TRP) co-founder and CEO Tony Charara talked with Proactive’s Tylah Tully about the company’s latest developments, including its phase three trial for TR987 and the commercial growth of TR Pro+. Charara provided an overview of TR987, Tissue Repair’s proprietary wound healing agent currently in phase three trials in Australia and the US. The company is focused on chronic wounds, particularly venous leg ulcers, where there has been no new drug approval in 25 years. "If we can replicate our phase two results, we believe TR987 could become a frontline therapy," Charara said. Alongside its drug development, Tissue Repair has launched TR Pro+, a topical treatment for post-procedure recovery in the aesthetics market. With adoption in nearly 300 clinics and monthly sales growth of 10%, the product is rapidly gaining traction. "The reception from physicians and patients has been outstanding," Charara noted. The company is now in advanced discussions for an Australian distributor and exploring expansion into global markets. While the phase three trial for TR987 is a key milestone, Tissue Repair is also diversifying through TR Pro+, ensuring multiple pathways for growth. #TissueRepair #ASXTRP #Biotech #WoundHealing #TR987 #TRProPlus #MedicalInnovation #Healthcare #Investing #StockMarket #ProactiveInvestors